Skinfriendly transdermal patch with good adhesion
Otto Bock Kunststoff has developed novel technology for transdermal patches
A novel method for manufacturing transdermal patches has been developed at the research laboratories of Otto Bock Kunststoff, in Duderstadt, Germany.
Transdermal patches have many applications: pain therapy, travel sickness, coronary heart disease and hormone replacement therapy to name a few. However, the disadvantage of patches can include frequent skin irritations or allergic reactions and, often, insufficient adhesion between patch and skin.
However, Otto Bock has introduced a patch that uses a novel adhesive and no solvents, reducing the occurrence of side effects on skin. Laboratory studies and clinical tests with the PUR transdermal patches have shown the patches have very good adhesive properties and are at the same time skin-friendly and cause no allergic reactions; they also release their active ingredients optimally.
The technology has been tested in a pilot facility in Duderstadt. The plant has a capacity of 20,000 PUR patches per day.
Examinations with scopolamine, a pain reliever and a hormone, testosterone, confirm good patch adherence and skin passage of the active ingredient, says the company.
‘We see different ways for continued development of the patented method. These range from partnership with a pharmaceuticals company to licensing of the production method. Initial discussions are promising, however we are still open to other options’, said Dr Peter Gansen, md and head of r&d at Otto Bock Kunststoff.